Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 14, 2014Leukemia & lymphoma/Leukemia and lymphoma

Myeloid derived suppressor cells are numerically, functionally and phenotypically different in patients with multiple myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

JFJames FavaloroRoyal Prince Alfred HospitalTLTulita LiyadipitiyaUniversity of Technology SydneyRBRoss BrownEnvironment and Climate Change Canada

Discussion

Loading...

Member takes

Overview

Observational study demonstrates elevated granulocytic myeloid-derived suppressor cells in progressive multiple myeloma, indicating a key driver of malignancy-induced immune dysfunction.

Key Points

  • To characterize the phenotype, frequency, and functional immunosuppressive capacity of myeloid-derived suppressor cells in patients with multiple myeloma.
  • Analyzed peripheral blood MDSC subsets (G-MDSCs and M-MDSCs) in patients with multiple myeloma and age-matched controls via flow cytometric immunophenotyping.
  • Assessed T-cell modulation by quantifying regulatory T cell induction and measuring lymphocyte proliferation inhibition using CFSE-tracking assays.
  • Evaluated MDSC frequencies in peripheral blood and harvest products following G-CSF administration during stem cell mobilization.
  • Granulocytic MDSCs were significantly elevated in the peripheral blood of patients with progressive multiple myeloma compared to controls.
  • Flow-sorted MDSCs induced regulatory T cell generation and produced dose-dependent inhibition of lymphocyte proliferation in both patients and controls.
  • G-CSF administration for stem cell mobilization increased circulating MDSC counts and concentrated these immunosuppressive cells within peripheral blood stem cell collections.

Cite This Study

Favaloro et al. (2014) studied this question.

synapsesocial.com/papers/6aaa49b25b0996a60171c6edhttps://doi.org/10.3109/10428194.2014.904511
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Subsets of Myeloid-Derived Suppressor Cells in Tumor-Bearing Mice2008 · 1,653 citations
  2. 2Decreased circulating myeloid-derived suppressor cell count at the engraftment is one of the risk factors for multiple myeloma relapse after autologous hematopoietic stem cell transplantation2024 · 5 citations
  3. 3Myeloid-derived suppressor cells in multiple myeloma: mechanistic insights and therapeutic implications2026
  4. 4Myeloid derived suppressor cells – a new therapeutic target in the treatment of cancer2013 · 290 citations
  5. 5Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell–suppressive activity2008 · 1,227 citations